SVAX will support Rubedo’s regulatory filings and conduct of Phase 2 clinical trials for lead program, RLS-1496, in the ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. MRNA research enabled ...

Research and Development Expenses -- $9.6 million in the third quarter of 2025, down from $12.3 million in Q3 2024, due to ...

Chennai: To prepare students to answer application-oriented questions from a young age, state school education department ...

With its inherent strengths, New York State is achieving gains in both domestic and international markets. | ...

Good morning, and welcome to the SELLAS Life Sciences R&D Day. As a reminder, this call is being recorded, and a replay will be made available on the SELLAS website following the conclusion of the ...

The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based Late-breaking Abstracts. SITC is proud to ...

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...

A new computational framework developed by a team with Professor Chris Wolverton maps atomic ordering to unlock ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

Cystic fibrosis (CF) therapeutics refer to treatments designed to manage and alleviate the symptoms of cystic fibrosis, a ...

Q3 2025 Earnings Call Transcript October 29, 2025 GSK plc beats earnings expectations. Reported EPS is $1.48, expectations ...